The Partnership for Health Analytics Research's study looked at predictions for 14 drugs launched since 2012 in various indications. On average, predictions were 11 times higher than the sales reported once the drugs hit the market
As some companies prepare to market their biosimilars, others are still in development. At the end of 2015, the IMS Institute noted that there were five biosimilars in the pre-registration phase of development.
Total spending on products whose patents expired between 2012 and 2015 declined by $14.2 billion last year, according to IMS Health’s Institute for Health Care informatics. And 2016 could bring about further cost reductions.